Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Inflammation or insulin resistance might be pathological mediators of cardiovascula...

Source: Diabetology and Metabolic Syndrome - March 24, 2020 Category: Endocrinology Authors: Sachiko Hattori Tags: Research Source Type: research